Kornimate/medical-research-clean huggingface dataset:
a randomized control trial of hinex jelly on the changes in muscle quality and quantity

Conditions: Nutrition, Healthy; Muscle Weakness; Elderly

Summary: taiwan is about to enter a super-aged society in 2025. the health problems of the elderly are getting more and more attention. among these geriatric issues, sarcopenia is an important issue. sarcopenia is the culprit of disability in old age. it is characterized by persistent and general loss of skeletal muscle mass and function throughout the body, which may lead to disability, decreased quality of life, and even inability to take care of yourself and an increased risk of death. human skeletal muscle decreases with age. after the age of 40, muscle mass will be lost at a rate of 8% per decade; after the age of 70, it will be lost at a faster rate of 15% per decade in average. although all elderly will lose muscle mass due to aging, the degree and speed of loss vary from person to person. in addition to aging, it may also be caused by chronic diseases. exercise intervention and nutritional intervention are the first choices for sarcopenia intervention. regarding nutritional requirements, the elderly need at least 15 grams of essential amino acids per day for muscle building. among them, leucine is the most important, which can increase protein production and reduce decomposition. foods rich in leucine include soybeans, fish or beef. however, elderly people may not be able to get enough protein from their daily diet smoothly, often because of dysphagia, such as dental problems or chewing and swallowing problems. therefore, oral nutritional supplements are relatively important for the improvement of muscle mass. nutritional supplement hinex jelly has 303 calories per serving, contains up to 15g of high-quality protein and a high amount of branched-chain amino acids, which is beneficial for muscle synthesis and tissue repair, plus a variety of minerals, vitamins, water-soluble dietary fiber, hydrolyzed collagen and other ingredients can strengthen nutritional supplements, maintain good health. in summary, this study intends to explore the effect of hinex jelly nutritional supplemental intervention on muscle mass quality and quantity changes by means of randomized intervention and controlled trials.


Eligibility criteria:
inclusion criteria: * adults over the age of 50 (include 50 years old). * can cooperate with the study. * no surgical intervention within 3 months. exclusion criteria: * those who have obvious difficulty in movement (such as amputation) and cannot cooperate with the study. * those who are equipped with pacemakers or internal electronic medical devices. * pregnant women. * use of drugs or interventional therapy that may affect changes in body weight or muscle mass (such as other oral nutritional supplements, medicine, weight reduction medicine, bariatric gastric endoscopy therapy, bariatric surgery, acupuncture, acupuncture, electrical stimulation, etc.). * allergic to dairy or soy products.
short- and long-term outcomes of robotic vs laparoscopic right colon cancer: a 10-year single-center retrospective study

Conditions: Robotic; Laparoscopic; Colon Cancer; Long-term Outcomes; Short-term Outcomes

Summary: the goal of this observational study is to evaluate the short-term outcomes and long-term outcomes of robot-assisted right colon group for cancer compared to laparoscopic-assisted right colon group. this is a large sample study based on ten years of clinical data. the main question it aims to answer is: what are the advantages of da vinci robot right hemicolectomy compared to laparoscopic right hemicolectomy, and is there a difference in long-term efficacy between the two methods.

colorectal cancer (crc) is highly prevalent worldwide. in china, crc ranks high among the population of men and women with cancer. the incidence and mortality rates of crc are rising quickly in developing countries, and it is the fourth most deadly cancer in the world. in particular, the right colon cancer (rcc) is continuously growing in china, and the early symptoms of rcc are not typical. one of the most useful ways for rcc is surgical is a surgical operation. along with the development of minimally invasive surgery, the use of laparoscopy for colon cancer is widely accepted and has become one symbolic surgical technology. studies have demonstrated that laparoscopic colonic surgery is related to reduced pain after operation, shorter rehabilitation time, shorter length of hospital stay, reduced the time of ileus after surgery, and reduced surgical site infection. nevertheless, laparoscopic surgery also has its shortcoming, including a limited range of motion, slow learning and growth, and physiological tremor cannot be eliminated.the emergence of robots has broken the inherent disadvantage of laparoscopy. it has achieved similar or better results in previous studies. based on these advantages, robotic surgery has received much attention from the surgeons. with the first robotic surgery in the field of colon cancer was reported in 2002, there are some studies proved the safety and feasibility by using robot,however, most studies with small sample sizes and with cases at a relatively early stage. therefore, the purpose of this study is to compare the short-term and long-term outcomes between rarc and larc in the treatment of right colon cancer in our center.

Eligibility criteria:
inclusion criteria: 1. the age is more than 18 years old and less than or equal to 85 years old 2. no distant metastasis (including pelvic cavity, peritoneum, liver, lung, brain, bone, distant lymph node metastasis, etc.) is judged by ultrasound, ct, pet-ct, etc 3. preoperative colonoscopy showing that the tumor was located in the ileocecal region, ascending colon, hepatic flexure, or transverse colon with pathology showing malignancy 4. signed informed consent. - exclusion criteria: 1. multiple primary colorectal cancer 2. recurrent right colon cancer 3. preoperative neoadjuvant chemotherapy 4. emergency surgery for intestinal obstruction, bleeding or perforation 5. incomplete data and missing follow-up data. -
impact of an immune modulator dimethyl fumarate on acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the investigators conduct this study to investigate whether oral administration of dimethyl fumarate, a food and drug administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with acute ischemic stroke.


Eligibility criteria:
inclusion criteria: 1. \>18 y of age; 2. acute onset of focal neurological deficit consistent with acute ischemic stroke; 3. measurable neurological deficit (nihss ≥ 5); 4. anterior-circulation ischemic stroke defined by magnetic resonance angiography (mra) and diffusion-weighted imaging(dwi); 5. onset of symptom to admission more than 4.5 h and less than 72 h. patients who arrived within 0-4.5 h poststroke were treated with other medications according to the best accepted medical treatment guidelines. exclusion criteria: 1. other diseases of the central nervous system 2. there has been neurological disability in the past (mrs score\>2) 3. difficulty swallowing 4. arrhythmia, atrioventricular block 5. use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs 6. macular edema 7. mra shows vertebral basilar artery obstruction 8. hemorrhagic stroke 9. patients who are known to have hypersensitivity to dimethyl fumarate or any excipients of this product 10. pregnant and lactating women

Keywords: dimethyl fumarate acute ischemic stroke immune modulation
a study of ff-10501-01 in combination with azacitidine in patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome (MDS)

Summary: the primary objective of the study is to determine the response rate according to the international working group response criteria for the combination of ff-10501-01 and azacitidine in patients previously untreated with hypomethylating agents, with int2/high risk mds according to the ipss, and intermediate/high/very-high risk mds according to the ipss-r, or who are otherwise candidates for treatment with azacitidine.

this is an open-label, simon 2-stage clinical study of the combination of ff-10501-01 and azacitidine in previously untreated patients with high-risk mds, or in patients with myelodysplastic syndrome (mds) who are otherwise candidates for treatment with azacitidine in the judgment of the investigator. the phase 2 portion of the trial will be preceded by a phase 1 "run-in" to evaluate the safety of the combination of ff-10501-01 plus azacitidine.

Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years of age 2. mds as determined by bone marrow aspirate and/or biopsy according to the who classification within 6 weeks of the first dose of study medication, with bone marrow blast counts of \< 20%. 3. int2/high-risk mds according to the ipss, intermediate/high/very high-risk mds according to the ipss-r, or otherwise eligible for treatment with azacitidine in the judgment of the investigator 4. ecog performance score of 0 or 1 5. adequate hepatic function as evidenced by ast/alt \< 3x the uln and total bilirubin \< 2x the uln for the reference lab 6. adequate renal function as evidenced by serum creatinine \ 50 ml/min exclusion criteria: 1. a current infection requiring treatment with intravenous antibiotics, anti-fungal agents, or anti-viral agents 2. previous treatment with a hypomethylating agent, an hdac inhibitor, or any other drug intended for the treatment of mds other than hematopoietic growth factors, immunosuppressive therapy or hydroxyurea. patients with 5q deletions may have received prior lenalidomide. 3. use of hematopoietic growth factors (erythropoietin, g-csf, gm-csf, thrombopoietin receptor agonists) or immunosuppressive treatments within 7 days of first dose of study medication 4. administration of any investigational agent within 5 half-lives of the agent; if the half-life is not known, use of such an agent within 2 weeks of the first dose of study medication 5. active infection with hiv or hepatitis b or c; patients with a history of such disorders should undergo serological testing to evaluate the activity of the infection

Keywords: myelodysplastic syndrome (mds)
short-term outcomes of transanal total mesorectal excision with structured training curriculums in china

Conditions: Rectal Cancer

Summary: transanal total mesorectal excision (tatme) is an alternative for mid-low rectal cancer. in china, this procedure has been performed in high-volume centers with structured training curriculums. this study aimed to evaluate the short-term outcomes during the initial implementation of the tatme procedure in high-volume centers who followed structured training curriculums in china.


Eligibility criteria:
inclusion criteria: * age between 18 and 75 years * american society of anesthesiologists (asa) score i to iii * a biopsy proven histological diagnosis of rectal carcinoma * undergoing transanal total mesorectal excision exclusion criteria: * pregnant or lactating women * synchronous rectal carcinoma * history of colorectal cancer or other malignant tumors * clinical evidence of metastasis * emergency procedure
junctional av ablation in crt-d: java-crt

Conditions: Systolic Heart Failure; Atrial Fibrillation (Permanent)

Summary: cardiac resynchronization therapy (crt) is a demonstrably effective device intervention for patients with heart failure with reduced ejection fraction and specific indication. however, many patients with heart failure (hf) are unable to maintain sinus rhythm and approximately 30-36% of crt patients are in atrial fibrillation (af).

this study is designed to evaluate if patients with af indicated for crt will have significant reduction in left ventricular end-systolic volume when randomized to atrioventricular junction (avj) ablation. in this study, subjects will be randomized to receive crt-d or crt-d with avj ablation. randomization will be stratified by enrolling center (1:1 ratio).

Eligibility criteria:
inclusion criteria: * optimal pharmacologic therapy is defined by published guidelines from the american heart association and the american college of cardiology * initial implantation of crt-d or prior implantation of crt-d within one year * ischemic or nonischemic cardiomyopathy * lvef ≤ 35% * nyha class ii-iv (ambulatory) * qrs ≥ 120 ms for lbbb and ≥ 150 ms for non-lbbb patients * continuous af \> 3 months when no further efforts to restore sinus rhythm are feasible or pursued exclusion criteria: * ventricular rate \> 110 bpm at rest despite maximal medical therapy * ventricular rate \< 50 bpm at rest * heart block/symptomatic bradycardia that necessitates permanent pacing * acute coronary syndrome or coronary artery bypass surgery within 12 weeks * severe aortic or mitral valvular heart disease * prior avj ablation * any medical condition likely to limit survival to \< 1 year * patients with acc/aha stage d refractory class iv symptoms listed for transplant or requiring inotropic support * contraindication to systematic anticoagulation * renal failure requiring dialysis * af due to reversible cause e.g. hyperthyroid state * pregnancy * participation in other clinical trials that will affect the objectives of this study * history of non-compliance to medical therapy * inability or unwillingness to provide informed consent * patients with short-lived af or those in sinus rhythm are ineligible

Keywords: atrial fibrillation crt av junction ablation lvesv
evaluation of the efficacy and tolerability of clobetasol propionate foam compared to vehicle foam

Conditions: Psoriasis

Summary: the purpose of the study is to compare the efficacy and safety of clobetasol propionate to that of its vehicle in the treatment of mild to moderate plaque-type psoriasis.

the purpose of the study is to compare the efficacy and safety of clobetasol propionate to that of its vehicle in the treatment of mild to moderate plaque-type psoriasis. this is a multi-center, double blind, randomized, parallel designed study which consists of 2 weeks of treatment and a follow-up visit 2 weeks later.

Eligibility criteria:
inclusion criteria: * outpatient, male or female of any race, and at least 12 years of age. female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study. * mild to moderate, plaque-type psoriasis * target lesion on the trunk or extremities (excluding palms/soles, elbows, or knees) with a score of 2 or 3 for each of erythema, scaling and plaque thickness * able to understand the requirements of the study and sign informed consent/hipaa authorization forms. subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian. exclusion criteria: * female subjects who are pregnant (positive urine pregnancy test) breast feeding or who are of childbearing potential and not practicing a reliable method of birth control * known allergy to clobetasol propionate or other topical corticosteroids; or to any component of the investigational formulations * subjects who have not complied with the proper wash-out periods for prohibited medications * medical condition that in the opinion of the investigator, contraindicates the subject's participation in the clinical study * skin disease/disorder that might interfere with the study related diagnosis or evaluations * evidence of recent alcohol or drug abuse * history of poor cooperation, non-compliance with medical treatment or unreliability

Keywords: psoriasis plaque type psoriasis
study of resection combined with stereotactic radiosurgery for 1 to 3 brain metastases

Conditions: Neoplasm Metastasis

Summary: this study is to look more closely at the tumor removed during your surgery, and to follow your condition after your treatment. the purpose of this study is to determine what side effects are common or more rare from this treatment, how well the treatment has worked for you, and to track whether you develop other brain metastases.


Eligibility criteria:
inclusion criteria: * patients must have a previously histopathologically proven diagnosis of malignancy. * patients must be evaluated by neurosurgery and radiation oncology * patients must have 1-3 brain metastases seen on mri or ct imaging. at least one brain metastases must be considered resectable by craniotomy as determined by the treating neurosurgeon. brain lesion resection must be considered standard of care. a not uncommon situation is for a patient to undergo resection of a solitary metastasis, but prove to have more lesions on subsequent mris (perhaps too small to be seen on a pre-operative mri). these patients will be eligible if the total number of lesions is 1-3. * all lesions must be treatable by srs as determined by the treating neurosurgeon and radiation oncologist. * all lesions must be \<4 cm in greatest dimension. for patients with more than 1 brain metastases, only 1 lesion can exceed 3 cm in greatest dimension. * in patients treated to the post-op surgical cavity, this cavity must be encompassed by a ctv of \<5 cm. * patients must have a karnofsky performance status ≥60. * extracranial disease must not be considered imminently life threatening (\<2 month anticipated survival from extracranial disease). * patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. exclusion criteria: * kps\<60 * life expectancy \> 2 months

Keywords: brain metastases
radiation dose study of concurrent chemoradiotherapy with cisplatin plus fluorouracil in oesophageal cancer

Conditions: Esophageal Neoplasms

Summary: the objective of this study is to determine the optimal radiation dosage used in concurrent chemo-radiotherapy in chinese population. a dose climbing experiment is carried out with an initiate dose of 50gy conventionally applied in western countries.

esophageal cancer (ec) continues to be a major health burden worldwide. the 5-year survival rates for esophageal cancer have remained less than 15% over decades, probably because of ineffective therapies and the detection of late-stage cancers. concurrent chemo-radiotherapy was established as one of the viable options for therapy of patients with localized ec following the results from the landmark trial of the radiation therapy oncology group (rtog) 85-01 trial, showing a significant survival advantage of concurrent chemoradiation over radiation alone. the use of radiochemotherapy with cisplatin and 5-fluorouracil (5-fu) is a well-accepted standard for the definitive treatment of esophageal cancer in china which has also been demonstrated efficacy and good tolerability internationally. the ajcc recommended dose range of radiotherapy for concurrent therapy is 45-50.4gy. moreover, (rtog) 85-01 trial also established 50.4 gy as the standard dose of radiation to be administered concurrently with chemotherapy. however, the appropriate dose of radiation fit for chinese remains controversial. due to insufficient evidence of ebm, radiation therapist in china always prescribe a radiation dosage by their own experience. dosages (e.g. 60-64gy) significantly higher than the international standard is commonly used in chinese ec patients which lead to a greater likelihood of toxicity. thus chinese oncologists are urgent to reach a consensus about radiation dosage in the standard treatment of local advanced ec.

Eligibility criteria:
inclusion criteria: 1. biopsy-proven squamous cell carcinoma or adenocarcinoma of thoracic or cervical esophagus or gastroesophageal junction esophagus, including the gastroesophageal junction 2. measurable lesion 3. age \> 18 years 4. karnofsky performance score \> 70 5. life expectancy \> 3 months 6. adequate bone marrow function (white blood cell \[wbc\] count ≥ 3.5 109/l, neutrophil count ≥ 2.0 109/l, and platelet count ≥ 100 109/l), adequate renal function (creatinine ≤ 2 mg/dl or creatinine clearance ≥ 50 ml/min), and normal liver function (aspartate aminotransferase and alanine aminotransferase less than two times the upper limit of normal, total serum bilirubin ≤ 1.5 mg/dl). exclusion criteria: 1. prior systemic chemotherapy for ec 2. evidence of distant metastatic disease 3. evidence of uncontrolled medical conditions (e.g.,serious infection,grade 4 hypertension,congestive heart failure) 4. a history of concomitant or previous malignancy. 5. physical evidence of peripheral neuropathy or hearing loss
smoking while on transdermal nicotine replacement therapy: effects on craving and cessation

Conditions: Nicotine Dependence

Summary: smoking while on nicotine patches will help subjects to reduce their expired carbon monoxide levels from the levels they were before they started using the patch. subjects will also decrease their daily consumption of cigarettes.

subjects who smoke while on an individually dosed tnrt will reduce their expired carbon monoxide levels from pre- to post-treatment conditions. they will also decrease their daily consumption of cigarettes.

Eligibility criteria:
inclusion criteria: * at least 19 years of age * male or female * have intention to quit smoking within the next 6 months * smoke 10 or more cigarettes per day exclusion criteria: * pregnant or not using an adequate enough method of birth control to ensure that they are not at risk of becoming pregnant * breastfeeding * have any generalized skin disorders * are in an immediate post-myocardial infarction period or have life-threatening arrhythmias, have severe or worsening angina pectoris or have had a recent cerebral vascular accident * are using additional nicotine replacement therapies or any other smoking cessation pharmacotherapy * any clinically significant ecg abnormalities * any known hypersensitivity to components of the transdermal system

Keywords: nicotine dependence, transdermal nicotine patch, smoking while receiving nicotine replacement, comorbidities
the value of pet/ct in diagnosing residual disease in patients with spinal infection

Conditions: Spondylodiscitis

Summary: mri has shoved little correlation with the clinical finding during treatment of spondylodiscitis (infection in the vertebrae and/or discs). since pet/ct is almost as good as mri in diagnosing spondylodiscitis the hypothesis and this study is that pet/ct is better in predicting residual disease in patients with spondylodiscitis. preliminary study.

in the last years there has been reported increasing incidence of spondylodiscitis. the increase is mainly thought to be caused by the increasing elderly population and the increasing amount of spinal instrumentation in this population. the symptoms range from backache to severe neurological deficits. up to 1/3 of cases are reported to be culture negative and cases can therefore be difficult to diagnose. mri is thought to be the main imaging technique to visualise infection. but with the increasing availability of 18-f fdg pet/ct, it is reported to be nearly as efficient to diagnose spinal infection. during the long antibiotic treatment of spondylodiscitis, the clinicians have no real good imaging technique to predict residual disease since mri during the remodelling fase of the spine will mimic no difference or worsening. since 18-f-fdg pet marks areas with a high amount of inflammatory cells it may also be faster in returning to normal images and therefore correlates better to actual status than mri. some of the purposes of this study are therefore: * to describe changes on pet/ct and mri at index and after 4, 8 12 and 26 weeks and compare these to the clinical findings as well as inflammatory biomarkers. * to investigate the correlation between normalisation of inflammatory biomarkers and changes on mri and pet/ct.

Eligibility criteria:
inclusion criteria: * first case of infectious spondylodiscitis * mri or 18-f-fdg pet/ct compatible with spondylodiscitis * overall assessment compatible with spondylodiscitis exclusion criteria: * previous spinal infection (e.g. spondylodiscitis; epidural abscess) * spinal operation in the previous 6 months * spinal foreign body * current malignant disease